REMARKS

This is a full and timely response to the final Office Action mailed April 13, 2004, and to the Advisory Action mailed on July 8, 2004. The final Office Action and Advisory Action have rejected Claims 1-24. By the present amendment and response, independent claims 1, 11, and 20 have been amended, and claims 1-24 remain pending in the application. The prior rejection of the claims is respectfully traversed by the present response. This response is concurrently filed with a Request for Continued Examination, and consideration of the present amendments and remarks is requested. Since the amended claims are neither taught or suggested by the cited references of the Office Action, all of the pending claims are patentable over the cited art.

I. CLAIMS 1, 11, 20 ARE DIRECTED TO "ACCELERATING A HEALING PROCESS"

Independent claims 1, 11, and 20 have been amended to relate to "accelerating a healing process for" an injury rather than "therapeutically treating" an injury. The term "accelerating a healing process for" an injury excludes tissue destruction, and therefore the claims are distinguished from the cited references.

II. THE REJECTION UNDER 35 U.S.C. 103(a)

On page 2, the Office Action has rejected claims 1-6, 11, 15-21, and 23-24 under 35 U.S.C. § 103(a) as being unpatentable over U.S. Patent No. 6,088,613 to Unger ("the '613 patent" or "Unger") in view of Talish et al. Applicants respectfully submit this argument from the prior response, and request reconsideration and withdrawal of the rejection.

Claims 1 and 20 each recite a "method for therapeutically treating an injury using ultrasound," and claim 11 recites a "kit for therapeutically treating an injury using ultrasound."

U.S. Patent Application Serial No. 09/980,329

Applicant: Winder, et al.

Amendment and Response to Office Action

Page 8 of 9

The Applicant's specification specifically discloses that the claimed invention utilizes "low

intensity acoustic energy to accelerate the healing process for treating bone and tissue injuries."

Specification, p. 6, line 15-26 (underlining supplied). In contrast, Unger recites a method that

utilizes ultrasonic energy to target desired regions of gas-filled vesicles, wherein the "vesicles

lower the cavitation threshold such that cavitation will occur within the target tissues at a low

energy threshold resulting in tissue destruction." Unger, Col. 10, lines 30-45 (underlining

supplied). Unger also discloses use of particular vesicles for "targeted intravascular use, e.g., to

bind to a certain tissue such as a tumor." Col. 15, lines 15-22. Again, Unger appears to relate to

destroying tissue, such as a tumor. In one specific example disclosed by Unger, high energy

ultrasound is applied to ectopic fetal tissue in a 25 year old female patient with a suspected

ectopic pregnancy. "By virtue of increased absorption if [sic] sound energy caused by the vesicles

the ectopic fetal tissue is then destroyed by the ultrasound energy." Col. 40, lines 22-60

(underlining supplied). As shown in each of the citations from Unger, Unger relates to applying

ultrasound for the purpose of tissue destruction rather than for the therapeutic purpose such as

accelerating the healing process for treating bone and tissue injuries as in the Applicant's claimed

invention. Since Unger relates to tissue destruction rather than treatment of an injury, Unger

neither discloses nor suggests the Applicant's claimed invention.

Claims 2-10, 12-19, and 21-24 are ultimately dependent from either claims 1, 11 or 20,

for which arguments of patentability have been advanced above. Therefore, dependent claims

2-10, 12-19, and 21-24 should also be allowable over the cited art.

ATLLIB01 1782747.1

U.S. Patent Application Serial No. 09/980,329

Applicant: Winder, et al.

Amendment and Response to Office Action

Page 9 of 9

CONCLUSION

Claims 1-24 are now in condition for allowance. The Examiner is invited and encouraged to contact the undersigned attorney of record at (404) 815-6048 if such contact will facilitate a Notice of Allowance. If any additional fees are due, the Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, to Deposit Account No. 11-0855.

Respectfully submitted,

Christopher J. Chan Reg. No. 44,070

Attorney for Assignee

DATED: 5 AUGUST 2004

KILPATRICK STOCKTON LLP

1100 Peachtree Street

Suite 2800

Atlanta, Georgia 30309-4530

(404) 815-6500

(404) 815-6555 (fax)

Attorney Docket No.: 41482/205543